Editorial review · United States
Afamelanotide
Source review:
Approval and product status
An FDA-approved implant exists for a rare-disease indication
Scenesse is not the same as every tanning peptide or injection. Scenesse is a healthcare-professional-administered implant. It is not equivalent to tanning peptides, compounded injections, or other melanocortin analogues.
This is the status described in the dated review. It is not a live FDA database check.
What was measured in people?
- Health outcomes · Strong
- Randomized trials support pain-free light-exposure and quality-of-life outcomes in adults with EPP.
- Body effects · Strong
- The approved implant's pharmacology and melanocortin-1 activity are characterized.
A change in a hormone or body signal does not by itself prove a health benefit.
Limits that matter
Not independently medically reviewed. This tool does not recommend treatment.
The implant is administered by trained healthcare professionals and the label calls for skin monitoring. This guide provides no implant or cosmetic-use instructions.
Still unknown: The approval does not establish general tanning, cosmetic anti-aging, athletic, or other disease benefits. It does not validate different melanocortin peptides.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Approval claims, with their sources
“Scenesse is an approved cosmetic tanning implant.”
Misleading. Its approval is for pain-free light exposure in adults with EPP, not cosmetic tanning.
Applies to: The current FDA-approved indication.
Exact product records in this review
These are selected records, not every product or form. A route means how a product enters the body.
Scenesse
- Form
- Controlled-release implant
- Route
- Subcutaneous implant administered by a trained professional
- Use and limits
- Increase pain-free light exposure in adults with erythropoietic protoporphyria and a history of phototoxic reactions.
Published label: 2024 label
Read the published Scenesse FDA label (PDF)What the research shows
Randomized trials in erythropoietic protoporphyria, or EPP, reported more pain-free light exposure and improvements in disease-specific quality of life. FDA approved Scenesse for a corresponding adult population.
Read all Afamelanotide claims and their limitsSources used in the full review
A source is not support for every claim. Use the claim links above or the full review to check what each source supports.
- SCENESSE (afamelanotide) prescribing information
U.S. Food and Drug Administration · Drug label · 2024
Source accessed
- Afamelanotide for erythropoietic protoporphyria
PubMed · New England Journal of Medicine · Randomized trial · 2015
Source accessed
- Afamelanotide orphan drug designation and approval
U.S. Food and Drug Administration · Regulatory · 2019
Source accessed